SCHEMBL1669870

SCHEMBL1669870

Brc1ccc(C2[CH]C2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 6/20 0.46
RCOR1 Q9UKL0 3/20 0.46
KCNH2 Q12809 2/20 0.46
MAOB P27338 2/20 0.46
KDM1B Q8NB78 1/20 0.46
CYP2A6 P11509 1/20 0.44
HTR2C P28335 2/20 0.40
HTR2B P41595 2/20 0.40
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
KMT2A Q03164 1/20 0.37
TSHR P16473 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
HAO1 Q9UJM8 1/20 0.35
LIG1 P18858 1/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21433657 0.72 KDM1A (0.46) KDM1ARCOR1MAOBHTR2CHTR2B
SCHEMBL2103232 0.71
SCHEMBL1779485 0.71
SCHEMBL14313656 0.71 KDM1A (0.36) KDM1ARCOR1KCNH2MAOBKDM1B
SCHEMBL12295868 0.69 KDM1A (0.68) KDM1ARCOR1KCNH2MAOBKDM1B
SCHEMBL265495 0.69 KDM1A (0.48) KDM1ARCOR1KCNH2MAOBKDM1B
SCHEMBL14804315 0.69 KDM1A (0.48) KDM1ARCOR1KCNH2MAOBKDM1B
SCHEMBL4800650 0.69 TSHR (0.42) KDM1ARCOR1KCNH2MAOBKDM1B
SCHEMBL883113 0.69 KDM1A (0.68) KDM1ARCOR1KCNH2MAOBKDM1B
SCHEMBL6519587 0.69 TSHR (0.42) KDM1ARCOR1KCNH2MAOBKDM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1027692-C Process for producing dienamide derivative ROUSSEL UCLAF CO (FR) 1995-02-22 CN claimed
EP-2907802-B1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 EP disclosed
CN-109153636-A Cyclopropyl-amide compound as dual LSD1/HDAC inhibitor 朱比连特比利斯有限公司 2019-01-04 CN disclosed
US-9751885-B2 Cyclopropanamine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-05 US disclosed
US-20150266881-A1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-09-24 US disclosed
CN-102952056-A Heptafluoroisopropylphenyl group contained diphenyl pyrroline compound and its use SINOCHEM CORP 2013-03-06 CN disclosed
EP-2486002-A1 SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE Oryzon Genomics, S.A. (ES) 2012-08-15 EP disclosed
WO-2011042217-A1 SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE ORYZON GENOMICS S.A. (ES) 2011-04-14 WO disclosed
CN-101952267-A Cyclopropylamine Derivatives ABBOTT LAB 2011-01-19 CN disclosed
CN-1684960-B Delta1 pyrrolines used as pesticides BAYER CROPSCIENCE AG 2010-05-26 CN disclosed
CN-101472887-A Cyclopropylamine derivatives as modulators of the histamine H3 receptor ABBOTT LAB (US) 2009-07-01 CN disclosed
CN-1684960-A Delta1 pyrrolines used as pesticides BAYER CROPSCIENCE AG (DE) 2005-10-19 CN disclosed
CN-1491211-A Delta for controlling pests1-pyrrolines �ݶ�ũ�����ѧ�ɷݹ�˾ 2004-04-21 CN disclosed
CN-1466571-A Preparation of delta1Process for preparing pyrrolines �ݶ�ũ�����ѧ�ɷݹ�˾ 2004-01-07 CN disclosed
CN-1045576-A Pesticide WELLCOME FOUND (GB) 1990-09-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266881-A1 CYCLOPROPANAMINE COMPOUND AND USE THEREOF BHMT, HNMT, KDM1A KDM1A 3/4885RCOR1 111/4885KCNH2 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.